LuSeed Vascular

Executive Summary

LuSeed Vascular is an Israeli MedTech startup founded in 2020, developing the LuSeed DOME™, a minimally invasive intrasaccular device for treating cerebral aneurysms at bifurcations and sidewalls. The device features a proprietary braided mesh geometry that allows deployment from multiple angles without the need for dual antiplatelet therapy, aiming to simplify procedures, reduce complications, and improve occlusion rates compared to existing solutions. At the preclinical stage, the company targets neurovascular interventionists and hospitals with a focus on faster, safer aneurysm treatment. LuSeed has raised an undisclosed amount and operates with a team of 10-50 employees. Given the early development phase, the company faces significant regulatory and clinical validation hurdles, but its innovative approach addresses a clear unmet need in neurovascular intervention. Conviction is moderate, reflecting potential coupled with high execution risk.

Upcoming Catalysts (preview)

• Q1 2027First-in-human clinical study initiation65% success
• Q3 2027CE marking application or submission40% success
• Q2 2027Series A financing round or strategic partnership70% success